Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1901
Harvard Bioscience
HBIO
$30.3M
| $3.2M | ﹤0.01% |
103,213
+35,530
| +52% | +$957K |
|
|
OPI
1902
DELISTED
Office Properties Income Trust
OPI
| $3.2M | ﹤0.01% |
123,200
-211,600
| -63% | -$5.51M |
|
1903
Archrock
AROC
$6.08B
| $3.19M | ﹤0.01% |
+492,128
| New | +$2.57M |
|
1904
Asbury Automotive
ABG
$3.78B
| $3.19M | ﹤0.01% |
+41,200
| New | +$2.77M |
|
|
GBT
1905
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.18M | ﹤0.01% |
50,400
+42,300
| +522% | +$2.9M |
|
1906
Tredegar Corp
TG
$276M
| $3.18M | ﹤0.01% |
206,400
-21,300
| -9% | -$330K |
|
1907
BancFirst
BANF
$3.89B
| $3.18M | ﹤0.01% |
78,300
-43,600
| -36% | -$1.6M |
|
1908
Travelzoo
TZOO
$73.4M
| $3.18M | ﹤0.01% |
563,149
-57,700
| -9% | -$318K |
|
|
WPRT
1909
Westport Fuel Systems
WPRT
$33.4M
| $3.17M | ﹤0.01% |
255,575
-92,490
| -27% | -$1.03M |
|
|
CVET
1910
DELISTED
Covetrus, Inc. Common Stock
CVET
| $3.15M | ﹤0.01% |
+175,900
| New | +$2.31M |
|
1911
Axogen
AXGN
$2.62B
| $3.14M | ﹤0.01% |
339,807
+191,507
| +129% | +$1.72M |
|
1912
AdaptHealth
AHCO
$775M
| $3.14M | ﹤0.01% |
194,900
+143,400
| +278% | +$2.4M |
|
1913
Rimini Street
RMNI
$466M
| $3.14M | ﹤0.01% |
608,879
+167,100
| +38% | +$711K |
|
1914
Korn Ferry
KFY
$4.32B
| $3.12M | ﹤0.01% |
+101,400
| New | +$2.9M |
|
|
CTLT
1915
DELISTED
CATALENT, INC.
CTLT
| $3.12M | ﹤0.01% |
+42,500
| New | +$2.89M |
|
1916
Cushman & Wakefield Ltd
CWK
$3.38B
| $3.11M | ﹤0.01% |
+249,700
| New | +$2.81M |
|
1917
Amdocs
DOX
$6.18B
| $3.11M | ﹤0.01% |
51,100
-225,300
| -82% | -$13.9M |
|
|
BDSI
1918
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $3.1M | ﹤0.01% |
711,863
+33,463
| +5% | +$150K |
|
1919
Arvinas
ARVN
$587M
| $3.1M | ﹤0.01% |
92,500
-127,995
| -58% | -$5.43M |
|
1920
Kinder Morgan
KMI
$73.1B
| $3.09M | ﹤0.01% |
+203,431
| New | +$3.09M |
|
1921
MasterCraft Boat Holdings
MCFT
$605M
| $3.08M | ﹤0.01% |
161,727
-396,372
| -71% | -$4.99M |
|
1922
Coeur Mining
CDE
$19.3B
| $3.08M | ﹤0.01% |
605,628
-5,279,200
| -90% | -$24M |
|
1923
AZZ Inc
AZZ
$4.55B
| $3.07M | ﹤0.01% |
+89,400
| New | +$2.73M |
|
1924
CervoMed
CRVO
$36.9M
| $3.07M | ﹤0.01% |
41,957
+19,568
| +87% | +$1.19M |
|
|
GOL
1925
DELISTED
Gol Linhas Aéreas Inteligentes S.A. American Depositary Shares (Each representing Ten Preferred Shares)
GOL
| $3.07M | ﹤0.01% |
452,200
-2,362,420
| -84% | -$12.4M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.